5-Azacytidine [320-67-2]
Référence HY-10586-200mg
Conditionnement : 200mg
Marque : MedChemExpress
5-azacytidine (azacitidine; 5-azaC; ladakamycine) est un analogue nucléosidique de la cytidine qui inhibe spécifiquement la méthylation de l'ADN. 5-azacytidine est incorporée dans l'ADN pour piéger de manière covalente les ADN méthyltransférases et contribue à inverser les changements épigénétiques. 5-azacytidine induit l'autophagie cellulaire.
5-Azacytidin (Azacitidin; 5-AzaC; Ladakamycin) ist ein Nukleosidanalogon von Cytidin, das spezifisch die DNA-Methylierung hemmt. 5-Azacytidin wird in die DNA eingebaut, um DNA methyltransferases kovalent einzufangen, und trägt zur Umkehrung epigenetischer Veränderungen bei. 5-Azacytidin induziert die Zellautophagie.
5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes. 5-Azacytidine induces cell autophagy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Avis client
Based on 96 publication(s) in Google Scholar
Other Forms of 5-Azacytidine:
- 5-Azacytidine-15N4 Obtenir un devis
- 5-Azacytidine (Standard) Obtenir un devis
- •Nature. 2025 Jan;637(8045):461-469. [Abstract]
- •Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
- •Adv Mater. 2023 Sep 8;e2302503. [Abstract]
- •Drug Resist Updat. 2024 Jul 22:76:101120. [Abstract]
- •Adv Sci (Weinh). 2024 Oct 7:e2401931. [Abstract]
- •ACS Nano. 2024 Jul 22. [Abstract]
- •Adv Sci (Weinh). 2024 Mar 14:e2307940. [Abstract]
- •Nat Commun. 2023 Sep 19;14(1):5709. [Abstract]
- •Mol Cell. 2022 Sep 29;S1097-2765(22)00896-6. [Abstract]
- •Nat Commun. 2022 May 13;13(1):2672. [Abstract]
- •EBioMedicine. 2024 Jul.
- •Sci Adv. 2024 Apr 26;10(17):eadm7164. [Abstract]
- •Cell Rep Med. 2024 May 16:101580. [Abstract]
- •Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2321611121. [Abstract]
- •Sci Adv. 2024 Apr 17;10(16):eadi1782
- •Nano Lett. 2023 Oct 25;23(20):9437-9444. [Abstract]
- •J Exp Clin Cancer Res. 2023 May 19;42(1):127. [Abstract]
- •Leukemia. 2021 Jun 1. [Abstract]
- •Theranostics. 2021 Jan 1;11(5):2318-2333. [Abstract]
- •Cancer Res. 2020 Feb 1;80(3):406-417. [Abstract]
- •Cell Death Dis. 2024 Aug 27;15(8):627. [Abstract]
- •Cell Rep. 2023 Aug 1;42(8):112927. [Abstract]
- •Acta Biomater. 2023 Apr 21;S1742-7061(23)00220-9. [Abstract]
- •Int J Biol Macromol. 2022.
- •Sci Data. 2022 Oct 8;9(1):610. [Abstract]
- •Acta Pharmacol Sin. 2021 Apr 13. [Abstract]
- •Cell Commun Signal. 2019 Aug 14;17(1):94. [Abstract]
- •Cell Death Dis. 2018 Apr 27;9(5):497. [Abstract]
- •Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]
- •PLoS Pathog. 2024 Nov 25;20(11):e1012736. [Abstract]
- •Cell Biol Toxicol. 2024 Dec 21;41(1):9. [Abstract]
- •Arch Toxicol. 2024 May;98(5):1499-1513. [Abstract]
- •Comput Biol Med. 2023 Dec 21, 107889.
- •Cell Mol Life Sci. 2023 Oct 28;80(11):338. [Abstract]
- •Elife. 2023 Nov 6:12:e92142. [Abstract]
- •Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
- •Antioxid Redox Signal. 2021 Jul;35(1):1-20. [Abstract]
- •Ecotoxicol Environ Saf. 2020 Dec 1;205:111089. [Abstract]
- •PLoS Pathog. 2020 Mar 24;16(3):e1008429. [Abstract]
- •Mol Oncol. 2018 Feb;12(2):180-195. [Abstract]
- •Am J Physiol Cell Physiol. 2024 Sep 2. [Abstract]
- •ACS Pharmacol Transl Sci. 2024 Jul 30;7(8):2484-2495. [Abstract]
- •Cancer Cell Int. 2024 Jun 13;24(1):208. [Abstract]
- •iScience. 2024 May 3.
- •Hum Genet. 2024 Mar 19. [Abstract]
- •Sci Rep. 2023 Nov 9;13(1):19438. [Abstract]
- •Am J Sports Med. 2023 Oct 7:3635465231198501. [Abstract]
- •NPJ Breast Cancer. 2023 Aug 11;9(1):66. [Abstract]
- •Ann Clin Microbiol Antimicrob. 2023 Jun 26;22(1):49. [Abstract]
- •Mol Carcinog. 2023 May 5. [Abstract]
- •Int J Mol Sci. 2023 Mar 20;24(6):5896. [Abstract]
- •Cancers (Basel). 2023, 15(2), 417.
- •Int Immunopharmacol. 2022 Aug 6;111:109113. [Abstract]
- •Dig Liver Dis. 2021 Sep 26;S1590-8658(21)00772-6. [Abstract]
- •BMC Biol. 2021 Sep 7;19(1):192. [Abstract]
- •Pharmaceuticals. 2021, 14(8), 749.
- •Front Cell Dev Biol. 2021 Apr 30;9:667435. [Abstract]
- •Front Cell Dev Biol. 2021 Apr 30.
- •Nutr Metab. 2020 May 27;17:41. [Abstract]
- •J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- •Anal Biochem. 2024 Dec 3:115741. [Abstract]
- •Int J Hematol. 2024 Dec 5. [Abstract]
- •Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- •Funct Integr Genomics. 2024 Sep 17;24(5):161. [Abstract]
- •Heliyon. 2024 Aug 10;10(16):e36017. [Abstract]
- •Brain Res Bull. 2024 Apr 17:212:110954. [Abstract]
- •Genes (Basel). 2023 Oct 8, 14(10), 1916.
- •Gene. 2023 Oct 7:147887. [Abstract]
- •Breast Cancer Res Treat. 2023 Aug 28. [Abstract]
- •J Pediatr Surg. 2023 Feb 15.
- •Invest New Drugs. 2022 May 16. [Abstract]
- •PPAR Res. 2021 Apr 19.
- •PLoS One. 2019 Sep 6;14(9):e0222298. [Abstract]
- •SLAS Discov. 2018 Aug;23(7):687-696. [Abstract]
- •J Int Med Res. 2024 Mar;52(3):3000605241234567. [Abstract]
- •Patent. US20240344035A1
- •Patent. US20240344035A1.
- •University of Pittsburgh. 2024.
- •Discov Oncol. 2024 Jun 27;15(1):248. [Abstract]
- •Research Square Preprint. 2024 Jan 3.
- •bioRxiv. 2023 Nov 23.
- •SSRN. 2023 Sep 8.
- •SSRN. 2023 Jul 7.
- •bioRxiv. 2023 Feb 7.
- •bioRxiv. 2023 Jan 9.
- •Research Square Print. September 9th, 2022.
- •Dis Markers. 11 Jul 2022.
- •Research Square Preprint. 2021 Jun.
- •Research Square Preprint. 2021 Feb.
- •University of Colorado. Department of Molecular, Cellular and Developmental Biology. 2020 Dec.
- •Ann Transl Med. 2020 Mar;8(6):373. [Abstract]
- •Ann Transl Med. 2020 Mar;8(6):329. [Abstract]
- •Patent. US20180263995A1.
- •Harvard Medical School LINCS LIBRARY
-
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2022.
- 5-azacytidine (5-AzaC; 5 μM; 1, 2, 3 days) results in an increase in the expression of MYOD1 and MYOG during myoblast differentiation.
-
5-Azacytidine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129. [Abstract]
- The effects of treatment with the indicated epigenetic inhibitors on cleaved PARP (Clv-PARP) expression in both PC9/ER and HCC827/ER cells. β-actin is used as a loading control.